-
First Duchenne patient receives novel gene-editing therapy in trial
For the first time, a person with Duchenne muscular dystrophy (DMD) has been given an experimental gene-editing therapy, called PBGENE-DMD, that’s designed to treat the neurodegenerative disease by altering the patient’s own genetic code. Precision Biosciences, the U.S. company developing PBGENE-DMD, announced that dosing had begun in the Phase 1/2 FUNCTION-DMD clinical trial (NCT07429240). The…
-
Working hard on staying positive as my FSHD progresses
I stepped back onto the medical treadmill this year to determine if the pain in my right shoulder and elbow, as well as the weakness and stiffness in my right arm and hand, were the result of facioscapulohumeral muscular dystrophy (FSHD). I was hoping it was something else, something that might be treatable. I knew…








